Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antimycobacterial agents.

M H Cynamon1, S P Klemens

  • 1State University of New York Health Science Center, Syracuse.

Clinics in Chest Medicine
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

New antimycobacterial agents are crucial for treating disseminated Mycobacterium avium complex infections and tuberculosis. Research focuses on modifying existing drugs and developing novel therapies, including new drug delivery systems.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro susceptibility of nocardia species to cethromycin, clarithromycin and amikacin.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2003
Same author

Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis.

American journal of respiratory and critical care medicine·2001
Same author

Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.

Antimicrobial agents and chemotherapy·2000
Same author

Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model.

Antimicrobial agents and chemotherapy·2000
Same author

Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.

Antimicrobial agents and chemotherapy·2000
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • The rise of AIDS and tuberculosis has increased the need for effective antimycobacterial agents.
  • Mycobacterium avium complex infections are a significant concern, particularly in immunocompromised individuals.

Purpose of the Study:

  • To review the development of novel antimycobacterial agents.
  • To highlight potential therapeutic strategies for mycobacterial infections.

Main Methods:

  • Review of existing and emerging antimycobacterial drug classes.
  • Exploration of novel drug delivery systems and immunomodulators.
  • Emphasis on preclinical and clinical trial evaluations.

Main Results:

Related Experiment Videos

  • Development of new agents involves modifying existing drugs (e.g., aminoglycosides, macrolides) and creating new classes (e.g., 4-quinolones).
  • Liposome encapsulation and immunomodulators show promise for treating mycobacterial infections.
  • Nontuberculous mycobacterial diseases are a primary target for improved therapies.

    • Conclusions:

    • New antimycobacterial agents are essential, with significant impact expected for nontuberculous mycobacterial diseases.
    • Further studies in animal models and clinical trials are required to establish the role of these new agents.